JP2015528449A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015528449A5 JP2015528449A5 JP2015528817A JP2015528817A JP2015528449A5 JP 2015528449 A5 JP2015528449 A5 JP 2015528449A5 JP 2015528817 A JP2015528817 A JP 2015528817A JP 2015528817 A JP2015528817 A JP 2015528817A JP 2015528449 A5 JP2015528449 A5 JP 2015528449A5
- Authority
- JP
- Japan
- Prior art keywords
- hepatitis
- pharmaceutically acceptable
- infection
- composition
- acceptable agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261695040P | 2012-08-30 | 2012-08-30 | |
| US61/695,040 | 2012-08-30 | ||
| US201261703816P | 2012-09-21 | 2012-09-21 | |
| US61/703,816 | 2012-09-21 | ||
| PCT/CA2013/050377 WO2014032176A1 (en) | 2012-08-30 | 2013-05-17 | Methods for the treatment of hepatitis b and hepatitis d infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017217194A Division JP2018039834A (ja) | 2012-08-30 | 2017-11-10 | Ｂ型肝炎感染及びｄ型肝炎感染の治療組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015528449A JP2015528449A (ja) | 2015-09-28 |
| JP2015528449A5 true JP2015528449A5 (enExample) | 2016-06-02 |
| JP6270846B2 JP6270846B2 (ja) | 2018-01-31 |
Family
ID=50182316
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015528817A Active JP6270846B2 (ja) | 2012-08-30 | 2013-05-17 | Ｂ型肝炎感染及びｄ型肝炎感染の治療方法 |
| JP2017217194A Pending JP2018039834A (ja) | 2012-08-30 | 2017-11-10 | Ｂ型肝炎感染及びｄ型肝炎感染の治療組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017217194A Pending JP2018039834A (ja) | 2012-08-30 | 2017-11-10 | Ｂ型肝炎感染及びｄ型肝炎感染の治療組成物 |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US9133458B2 (enExample) |
| EP (1) | EP2890403A4 (enExample) |
| JP (2) | JP6270846B2 (enExample) |
| KR (2) | KR20150046309A (enExample) |
| CN (1) | CN104837501B (enExample) |
| AU (1) | AU2013308045B2 (enExample) |
| BR (1) | BR112015003985A2 (enExample) |
| CA (1) | CA2883785C (enExample) |
| CL (1) | CL2015000499A1 (enExample) |
| CR (1) | CR20150107A (enExample) |
| CU (1) | CU20150018A7 (enExample) |
| DO (1) | DOP2015000041A (enExample) |
| EC (1) | ECSP15007345A (enExample) |
| GT (1) | GT201500046A (enExample) |
| IL (1) | IL237173B (enExample) |
| IN (1) | IN2015DN01087A (enExample) |
| MX (1) | MX361522B (enExample) |
| MY (1) | MY172785A (enExample) |
| NZ (1) | NZ705730A (enExample) |
| PH (1) | PH12015500361B1 (enExample) |
| SG (1) | SG11201501255PA (enExample) |
| TW (1) | TWI620568B (enExample) |
| WO (1) | WO2014032176A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE054875T2 (hu) | 2012-05-18 | 2021-10-28 | Replicor Inc | Oligonukleotid kelátkomplex-polipeptid készítmények és eljárások |
| CN104837501B (zh) | 2012-08-30 | 2018-11-02 | 里普利科股份有限公司 | 治疗乙型肝炎及丁型肝炎感染的方法 |
| KR20170029577A (ko) * | 2014-07-10 | 2017-03-15 | 레플리코르 인코포레이티드 | B형 간염 및 d형 간염 바이러스 감염의 치료 방법 |
| WO2016030863A1 (en) | 2014-08-29 | 2016-03-03 | Glaxosmithkline Intellectual Property Development Limited | Compounds and methods for treating viral infections |
| US20160175245A1 (en) * | 2014-12-19 | 2016-06-23 | Mycotoxins Therapy, Llc | Treatment of diseases associated with mold and mycotoxin exposure |
| US20170137821A1 (en) | 2015-07-17 | 2017-05-18 | Arcturus Therapeutics, Inc. | Molecules and agents for treating hepatitis b virus |
| JP6924744B2 (ja) | 2015-07-17 | 2021-08-25 | アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 |
| CN108350455A (zh) * | 2015-07-29 | 2018-07-31 | 阿布特斯生物制药公司 | 用于使b型肝炎病毒基因表达沉默的组合物和方法 |
| WO2017059878A1 (en) * | 2015-10-07 | 2017-04-13 | Humabs Biomed Sa | Antibodies that potently neutralize hepatitis b virus and uses thereof |
| HK1255835A1 (zh) * | 2016-01-08 | 2019-08-30 | Arbutus Biopharma Corporation | 用於治疗乙型肝炎的治疗组合物及方法 |
| RS61944B1 (sr) | 2016-02-19 | 2021-07-30 | Eiger Biopharmaceuticals Inc | Lečenje infekcije hepatitis delta virusom sa interferonom lambda |
| TW201907009A (zh) * | 2017-05-31 | 2019-02-16 | 加拿大商艾爾布圖斯生技公司 | 用於治療b型肝炎之治療組成物及方法 |
| TWI815887B (zh) * | 2018-05-15 | 2023-09-21 | 美商愛彼特生物製藥股份有限公司 | 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法 |
| BR112021000538A2 (pt) | 2018-07-13 | 2021-04-06 | F. Hoffmann-La Roche Ag | Oligonucleotídeos para modular a expressão de rtel1 |
| US11166976B2 (en) | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| SI3898668T1 (sl) | 2018-12-19 | 2024-02-29 | Humabs Biomed Sa | Protitelesa, ki nevtralizirajo virus hepatitisa B in njihove uporabe |
| PT4285929T (pt) | 2018-12-20 | 2026-01-02 | Humabs Biomed Sa | Terapêutica de combinação contra o vhb |
| EP4081639A1 (en) * | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv |
| CN114507663B (zh) * | 2020-11-16 | 2026-07-17 | 浙江柏拉阿图医药科技有限公司 | 寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6030954A (en) | 1991-09-05 | 2000-02-29 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
| US20030206887A1 (en) | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| US20040054156A1 (en) | 1992-05-14 | 2004-03-18 | Kenneth Draper | Method and reagent for inhibiting hepatitis B viral replication |
| US20040127446A1 (en) * | 1992-05-14 | 2004-07-01 | Lawrence Blatt | Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication |
| US5646262A (en) | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
| CA2254931C (en) * | 1996-06-11 | 2007-04-10 | Yeda Research And Development Co. Ltd. | Human monoclonal antibodies to the hepatitis b surface antigen |
| IL118625A0 (en) * | 1996-06-11 | 1996-10-16 | Xtl Biopharmaceuticals Limited | Anti HBV antibodies |
| DE19725803C1 (de) | 1997-06-18 | 1999-02-11 | Deutsches Krebsforsch | HBV-gerichtete Antisense-Nukleinsäuren |
| US6670342B2 (en) | 2000-03-29 | 2003-12-30 | Georgetown University | Method of treating hepatitis delta virus infection |
| EA008940B1 (ru) * | 2002-09-13 | 2007-10-26 | Репликор, Инк. | Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей |
| US20070027099A1 (en) * | 2003-05-19 | 2007-02-01 | Lin Marie C | Gene therapy of HBV infection via adeno-associated viral vector mediated long term expression of small hairpin RNA (shRNA) |
| DK2270162T3 (en) | 2003-06-12 | 2019-01-21 | Alnylam Pharmaceuticals Inc | PRESERVED HBV AND HCV SEQUENCES USED FOR GEN-SILENCING |
| CN101084232A (zh) * | 2004-10-19 | 2007-12-05 | 里普利科股份有限公司 | 抗病毒寡核苷酸 |
| ES2651308T3 (es) * | 2009-10-16 | 2018-01-25 | Glaxo Group Limited | Inhibidores antisentido de HBV |
| WO2011047316A1 (en) | 2009-10-16 | 2011-04-21 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Nucleic acid sequences encoding expandable hiv mosaic proteins |
| CA2746981A1 (en) * | 2010-08-05 | 2012-02-05 | Replicor Inc. | Methods for inhibition of apolipoprotein h |
| JP5775581B2 (ja) | 2010-08-20 | 2015-09-09 | レプリコール インコーポレーティッド | オリゴヌクレオチドキレート錯体 |
| CN103889428A (zh) * | 2010-10-04 | 2014-06-25 | 肝炎与病毒研究所 | 乙型肝炎病毒抗原分泌的新型抑制剂 |
| SI3505528T1 (sl) | 2011-04-21 | 2021-04-30 | Glaxo Group Limited | Modulacija izražanja virusa hepatitisa B (HBV) |
| PT2726613T (pt) | 2011-06-30 | 2018-10-26 | Arrowhead Pharmaceuticals Inc | Composições e métodos para inibição da expressão de genes do vírus da hepatite b |
| HUE054875T2 (hu) | 2012-05-18 | 2021-10-28 | Replicor Inc | Oligonukleotid kelátkomplex-polipeptid készítmények és eljárások |
| AR091065A1 (es) | 2012-05-18 | 2014-12-30 | Replicor Inc | Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral |
| CN104837501B (zh) | 2012-08-30 | 2018-11-02 | 里普利科股份有限公司 | 治疗乙型肝炎及丁型肝炎感染的方法 |
-
2013
- 2013-05-17 CN CN201380045796.6A patent/CN104837501B/zh active Active
- 2013-05-17 EP EP13832690.5A patent/EP2890403A4/en not_active Withdrawn
- 2013-05-17 WO PCT/CA2013/050377 patent/WO2014032176A1/en not_active Ceased
- 2013-05-17 CA CA2883785A patent/CA2883785C/en active Active
- 2013-05-17 NZ NZ705730A patent/NZ705730A/en unknown
- 2013-05-17 AU AU2013308045A patent/AU2013308045B2/en active Active
- 2013-05-17 JP JP2015528817A patent/JP6270846B2/ja active Active
- 2013-05-17 SG SG11201501255PA patent/SG11201501255PA/en unknown
- 2013-05-17 KR KR1020157007858A patent/KR20150046309A/ko not_active Ceased
- 2013-05-17 MY MYPI2015000437A patent/MY172785A/en unknown
- 2013-05-17 BR BR112015003985A patent/BR112015003985A2/pt not_active Application Discontinuation
- 2013-05-17 US US13/896,421 patent/US9133458B2/en active Active
- 2013-05-17 IN IN1087DEN2015 patent/IN2015DN01087A/en unknown
- 2013-05-17 MX MX2015002491A patent/MX361522B/es active IP Right Grant
- 2013-05-17 KR KR1020177032724A patent/KR102025679B1/ko not_active Expired - Fee Related
- 2013-05-17 TW TW102117614A patent/TWI620568B/zh not_active IP Right Cessation
-
2014
- 2014-08-01 US US14/449,173 patent/US9200283B2/en active Active
- 2014-08-01 US US14/449,174 patent/US9284556B2/en active Active
-
2015
- 2015-02-10 IL IL237173A patent/IL237173B/en active IP Right Grant
- 2015-02-18 PH PH12015500361A patent/PH12015500361B1/en unknown
- 2015-02-26 CU CUP2015000018A patent/CU20150018A7/es unknown
- 2015-02-26 DO DO2015000041A patent/DOP2015000041A/es unknown
- 2015-02-27 EC ECIEPI20157345A patent/ECSP15007345A/es unknown
- 2015-02-27 GT GT201500046A patent/GT201500046A/es unknown
- 2015-02-27 CL CL2015000499A patent/CL2015000499A1/es unknown
- 2015-02-27 CR CR20150107A patent/CR20150107A/es unknown
- 2015-09-15 US US14/854,200 patent/US9533003B2/en active Active
-
2017
- 2017-11-10 JP JP2017217194A patent/JP2018039834A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6922030B2 (ja) | Ｂ型肝炎およびｄ型肝炎ウイルス感染の治療のための方法 | |
| TWI620568B (zh) | 用於治療ｂ型肝炎及ｄ型肝炎感染之方法 | |
| JP2021533767A5 (enExample) | ||
| FI3837366T3 (fi) | Hepatiitti b -viruksen (hbv) dsrna-ainekoostumuksia ja niiden käyttömenetelmiä | |
| JP2013522302A5 (enExample) | ||
| JP2017521433A5 (enExample) | ||
| JP2015517504A5 (enExample) | ||
| JP2025500860A5 (enExample) | ||
| AU2020415307A1 (en) | Method of treating virus infection using a TLR7 agonist | |
| Stein et al. | Drug targets in hepatitis B virus infection | |
| JP2024544532A5 (enExample) | ||
| De Clercq | Interferon and its inducers—a never-ending story:“old” and “new” data in a new perspective | |
| WO2022022158A1 (zh) | 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用 | |
| HK40065449A (en) | Methods for the treatment of hepatitis b and hepatitis d virus infections | |
| JPWO2004083186A1 (ja) | ウイルス性肝炎治療剤及び制癌剤 |